Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Heart Disease Treatment Costs $100 Billion per Year in the US

L.A. McKeown

July 30, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Conference News SCCT 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Yael L. Maxwell

July 22, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

No Change in HF Outcomes When Private Equity Buys the Hospital

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Michael O'Riordan

June 16, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Advertisement

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Heart Disease Treatment Costs $100 Billion per Year in the US

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

FDA Approves Triple Therapy Polypill for High Blood Pressure

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content